89Bio

89bio is a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis and other liver and metabolic disorders. The company's lead product candidate is BIO89-100, a novel long-acting glycopegylated fibroblast growth factor 21 analogue.